Cargando…

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model

BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options. Experimental preclinical models that recapitulate their tumors of origin can accelerate target identification, thereby potentially improving therapeutic efficacy. Patient-derived xenog...

Descripción completa

Detalles Bibliográficos
Autores principales: Matossian, Margarite D., Burks, Hope E., Elliott, Steven, Hoang, Van T., Bowles, Annie C., Sabol, Rachel A., Wahba, Bahia, Anbalagan, Muralidharan, Rowan, Brian, Abazeed, Mohamed E., Bunnell, Bruce A., Moroz, Krzysztof, Miele, Lucio, Rhodes, Lyndsay V., Jones, Steven D., Martin, Elizabeth C., Collins-Burow, Bridgette M., Burow, Matthew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407287/
https://www.ncbi.nlm.nih.gov/pubmed/30845999
http://dx.doi.org/10.1186/s12885-019-5401-2
_version_ 1783401519957147648
author Matossian, Margarite D.
Burks, Hope E.
Elliott, Steven
Hoang, Van T.
Bowles, Annie C.
Sabol, Rachel A.
Wahba, Bahia
Anbalagan, Muralidharan
Rowan, Brian
Abazeed, Mohamed E.
Bunnell, Bruce A.
Moroz, Krzysztof
Miele, Lucio
Rhodes, Lyndsay V.
Jones, Steven D.
Martin, Elizabeth C.
Collins-Burow, Bridgette M.
Burow, Matthew E.
author_facet Matossian, Margarite D.
Burks, Hope E.
Elliott, Steven
Hoang, Van T.
Bowles, Annie C.
Sabol, Rachel A.
Wahba, Bahia
Anbalagan, Muralidharan
Rowan, Brian
Abazeed, Mohamed E.
Bunnell, Bruce A.
Moroz, Krzysztof
Miele, Lucio
Rhodes, Lyndsay V.
Jones, Steven D.
Martin, Elizabeth C.
Collins-Burow, Bridgette M.
Burow, Matthew E.
author_sort Matossian, Margarite D.
collection PubMed
description BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options. Experimental preclinical models that recapitulate their tumors of origin can accelerate target identification, thereby potentially improving therapeutic efficacy. Patient-derived xenografts (PDXs), due to their genomic and transcriptomic fidelity to the tumors from which they are derived, are poised to improve the preclinical testing of drug-target combinations in translational models. Despite the previous development of breast and TNBC PDX models, those derived from patients with demonstrated health-disparities are lacking. METHODS: We use an aggressive TNBC PDX model propagated in SCID/Beige mice that was established from an African-American woman, TU-BcX-2 K1, and assess its metastatic potential and drug sensitivities under distinct in vitro conditions. Cellular derivatives of the primary tumor or the PDX were grown in 2D culture conditions or grown in mammospheres 3D culture. Flow cytometry and fluorescence staining was used to quantify cancer stem cell-like populations. qRT-PCR was used to describe the mesenchymal gene signature of the tumor. The sensitivity of TU-BcX-2 K1-derived cells to anti-neoplastic oncology drugs was compared in adherent cells and mammospheres. Drug response was evaluated using a live/dead staining kit and crystal violet staining. RESULTS: TU-BcX-2 K1 has a low propensity for metastasis, reflects a mesenchymal state, and contains a large burden of cancer stem cells. We show that TU-BcX-2 K1 cells have differential responses to cytotoxic and targeted therapies in 2D compared to 3D culture conditions insofar as several drug classes conferred sensitivity in 2D but not in 3D culture, or cells grown as mammospheres. CONCLUSIONS: Here we introduce a new TNBC PDX model and demonstrate the differences in evaluating drug sensitivity in adherent cells compared to mammosphere, or suspension, culture. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5401-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6407287
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64072872019-03-21 Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model Matossian, Margarite D. Burks, Hope E. Elliott, Steven Hoang, Van T. Bowles, Annie C. Sabol, Rachel A. Wahba, Bahia Anbalagan, Muralidharan Rowan, Brian Abazeed, Mohamed E. Bunnell, Bruce A. Moroz, Krzysztof Miele, Lucio Rhodes, Lyndsay V. Jones, Steven D. Martin, Elizabeth C. Collins-Burow, Bridgette M. Burow, Matthew E. BMC Cancer Research Article BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options. Experimental preclinical models that recapitulate their tumors of origin can accelerate target identification, thereby potentially improving therapeutic efficacy. Patient-derived xenografts (PDXs), due to their genomic and transcriptomic fidelity to the tumors from which they are derived, are poised to improve the preclinical testing of drug-target combinations in translational models. Despite the previous development of breast and TNBC PDX models, those derived from patients with demonstrated health-disparities are lacking. METHODS: We use an aggressive TNBC PDX model propagated in SCID/Beige mice that was established from an African-American woman, TU-BcX-2 K1, and assess its metastatic potential and drug sensitivities under distinct in vitro conditions. Cellular derivatives of the primary tumor or the PDX were grown in 2D culture conditions or grown in mammospheres 3D culture. Flow cytometry and fluorescence staining was used to quantify cancer stem cell-like populations. qRT-PCR was used to describe the mesenchymal gene signature of the tumor. The sensitivity of TU-BcX-2 K1-derived cells to anti-neoplastic oncology drugs was compared in adherent cells and mammospheres. Drug response was evaluated using a live/dead staining kit and crystal violet staining. RESULTS: TU-BcX-2 K1 has a low propensity for metastasis, reflects a mesenchymal state, and contains a large burden of cancer stem cells. We show that TU-BcX-2 K1 cells have differential responses to cytotoxic and targeted therapies in 2D compared to 3D culture conditions insofar as several drug classes conferred sensitivity in 2D but not in 3D culture, or cells grown as mammospheres. CONCLUSIONS: Here we introduce a new TNBC PDX model and demonstrate the differences in evaluating drug sensitivity in adherent cells compared to mammosphere, or suspension, culture. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5401-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-03-07 /pmc/articles/PMC6407287/ /pubmed/30845999 http://dx.doi.org/10.1186/s12885-019-5401-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Matossian, Margarite D.
Burks, Hope E.
Elliott, Steven
Hoang, Van T.
Bowles, Annie C.
Sabol, Rachel A.
Wahba, Bahia
Anbalagan, Muralidharan
Rowan, Brian
Abazeed, Mohamed E.
Bunnell, Bruce A.
Moroz, Krzysztof
Miele, Lucio
Rhodes, Lyndsay V.
Jones, Steven D.
Martin, Elizabeth C.
Collins-Burow, Bridgette M.
Burow, Matthew E.
Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
title Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
title_full Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
title_fullStr Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
title_full_unstemmed Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
title_short Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
title_sort drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407287/
https://www.ncbi.nlm.nih.gov/pubmed/30845999
http://dx.doi.org/10.1186/s12885-019-5401-2
work_keys_str_mv AT matossianmargarited drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT burkshopee drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT elliottsteven drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT hoangvant drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT bowlesanniec drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT sabolrachela drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT wahbabahia drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT anbalaganmuralidharan drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT rowanbrian drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT abazeedmohamede drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT bunnellbrucea drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT morozkrzysztof drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT mielelucio drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT rhodeslyndsayv drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT jonesstevend drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT martinelizabethc drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT collinsburowbridgettem drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel
AT burowmatthewe drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel